Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis

Journal of Immunological Methods

Volumn 348, Issue 1-2, 2009, Pages 36-41

  Palframan, Roger ^a   Airey, Michael ^a   Moore, Adrian ^a   Vugler, Alex ^a   Nesbitt, Andrew ^a  

^a UCB   (United Kingdom)

Author keywords

Biofluorescence imaging; Certolizumab pegol; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; COLLAGEN TYPE 2; FLUORESCENT DYE; INFLIXIMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG TOLERABILITY; FLUORESCENCE ANALYSIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT DURATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, EXPERIMENTAL; COLLAGEN TYPE II; FLUORESCENCE; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICE; MICE, INBRED DBA; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MURINAE; MUS;

EID: 68549116988     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.06.009     Document Type: Article

References (19)

1. Alonso-Ruiz A., Pijoan J.I., Ansuategui E., Urkaregi A., Calabozo M., and Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC. Musculoskelet. Disord. 9 (2008) 52
2. Chapman A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev. 54 (2002) 531
3. Courtenay J.S., Dallman M.J., Dayan A.D., Martin A., and Mosedale B. Immunisation against heterologous type II collagen induces arthritis in mice. Nature 283 (1980) 666
4. Fleischmann R., Vencovsky J., van Vollenhoven R., Borenstein D., Box J., Coteur G., Goel N., Brezinschek H.P., Innes A., and Strand V. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 69 (2009) 805
5. Garrood T., and Pitzalis C. Targeting the inflamed synovium: the quest for specificity. Arthritis. Rheum. 54 (2006) 1055
6. Keystone E., van der Heijde D., Mason D., Landewe R., van Vollenhoven R., Combe B., Emery P., Strand V., Mease P.J., Desai C., and Pavelka K. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: the RAPID 1 study. Arthritis Rheum. 58 (2008) 3319
7. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., Fischkoff S.A., and Chartash E.K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50 (2004) 1400
8. Koch A.E. Angiogenesis as a target in rheumatoid arthritis. Ann. Rheum. Dis. 62 Suppl 2 (2003) ii60
9. Lee D.M., and Weinblatt M.E. Rheumatoid arthritis. Lancet 358 (2001) 903
10. Maeda H., Wu J., Sawa T., Matsumura Y., and Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control. Release 65 (2000) 271
11. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., St Clair E.W., Keenan G.F., van der H.D., Marsters P.A., and Lipsky P.E. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 50 (2004) 1051
12. McDonald D.M., and Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res. 62 (2002) 5381
13. Smolen J., Landewe R., Mease P., Brzezicki J., Mason D., Luijtens K., van Vollenhoven R., Kavanaugh A., Schiff M., Burmester G.R., Strand V., Vencovsky J., and van der Heijde D. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 69 (2009) 797
14. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., and Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther. 117 (2008) 244
15. Veronese F.M., and Pasut G. PEGylation, successful approach to drug delivery. Drug Discov. Today 10 (2005) 1451
16. Walsh D.A., Wade M., Mapp P.I., and Blake D.R. Focally regulated endothelial proliferation and cell death in human synovium. Am. J. Pathol. 152 (1998) 691
17. Wang D., Miller S.C., Sima M., Parker D., Buswell H., Goodrich K.C., Kopeckova P., and Kopecek J. The arthrotropism of macromolecules in adjuvant-induced arthritis rat model: a preliminary study. Pharm. Res. 21 (2004) 1741
18. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoh L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48 (2003) 35
19. Wunder A., Straub R.H., Gay S., Funk J., and Muller-Ladner U. Molecular imaging: novel tools in visualizing rheumatoid arthritis. Rheumatology (Oxford) 44 (2005) 1341